These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17510129)

  • 1. Clinton brokers deal to lower price of antiretrovirals.
    Abimbola S
    BMJ; 2007 May; 334(7602):1026. PubMed ID: 17510129
    [No Abstract]   [Full Text] [Related]  

  • 2. Patents versus patients? Antiretroviral therapy in India.
    Havlir DV; Hammer SM
    N Engl J Med; 2005 Aug; 353(8):749-51. PubMed ID: 16120852
    [No Abstract]   [Full Text] [Related]  

  • 3. Generic antiretroviral drugs--will they be the answer to HIV in the developing world?
    Kumarasamy N
    Lancet; 2004 Jul 3-9; 364(9428):3-4. PubMed ID: 15234833
    [No Abstract]   [Full Text] [Related]  

  • 4. Examining the production costs of antiretroviral drugs.
    Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
    AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. World Trade Organization still threatens supply of affordable AIDS drugs.
    Hagmann M
    Bull World Health Organ; 2002; 80(9):762-3. PubMed ID: 12378300
    [No Abstract]   [Full Text] [Related]  

  • 6. Call for action to secure universal access to ART in developing countries.
    Orsi F; Carrieri MP; Coriat B; Delaporte E; Moatti JP; Spire B; Taverne B; Barré-Sinoussi F
    Lancet; 2010 May; 375(9727):1693-4. PubMed ID: 20472168
    [No Abstract]   [Full Text] [Related]  

  • 7. Uganda cuts AIDS drug deal.
    IAPAC Mon; 2001 Feb; 7(2):40. PubMed ID: 11302022
    [No Abstract]   [Full Text] [Related]  

  • 8. Trans-Pacific trade pact triggers fears over drug prices.
    McCall C
    Lancet; 2015 Jun; 385(9986):2450-1. PubMed ID: 26122057
    [No Abstract]   [Full Text] [Related]  

  • 9. Prioritizing antiretrovirals for second-line therapy in resource-limited countries.
    Naidoo K
    AIDS Clin Care; 2008 May; 20(5):43. PubMed ID: 19230296
    [No Abstract]   [Full Text] [Related]  

  • 10. [HIV therapy: tenofir DF is available in 68 developing countries at production costs price].
    Med Klin (Munich); 2003 Jul; 98(7):XV-XVI. PubMed ID: 12945544
    [No Abstract]   [Full Text] [Related]  

  • 11. Companies reduce prices for HIV drugs in developing countries.
    Gottlieb S
    Bull World Health Organ; 2000; 78(6):862. PubMed ID: 10916926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain.
    James JS
    AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Affordable drugs for developing countries.
    Chong CY
    Hong Kong Med J; 2003 Apr; 9(2):148-9. PubMed ID: 12668831
    [No Abstract]   [Full Text] [Related]  

  • 14. Generics industry and doctors nervous over free trade deal.
    Burton B
    BMJ; 2004 May; 328(7449):1158. PubMed ID: 15142916
    [No Abstract]   [Full Text] [Related]  

  • 15. Closing the affordability gap for drugs in low-income countries.
    Steinbrook R
    N Engl J Med; 2007 Nov; 357(20):1996-9. PubMed ID: 18003957
    [No Abstract]   [Full Text] [Related]  

  • 16. TRIPS post-2005 and access to new antiretroviral treatments in southern countries: issues and challenges.
    Orsi F; D'Almeida C; Hasenclever L; Camara M; Tigre P; Coriat B
    AIDS; 2007 Oct; 21(15):1997-2003. PubMed ID: 17885289
    [No Abstract]   [Full Text] [Related]  

  • 17. A one-time-only combination: Emergency medicine exports and the TRIPS agreement under Canada's access to medicines regime.
    Weber A; Mills L
    Health Hum Rights; 2010 Jun; 12(1):109-22. PubMed ID: 20930258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
    Berger JM
    Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
    [No Abstract]   [Full Text] [Related]  

  • 19. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
    Spectar JM
    Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
    [No Abstract]   [Full Text] [Related]  

  • 20. Generic and branded drugs for the treatment of people living with HIV/AIDS.
    Bartlett JA; Muro EP
    J Int Assoc Physicians AIDS Care (Chic); 2007 Mar; 6(1):15-23. PubMed ID: 17329500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.